BioTech Medics, Inc. Profiled in Major BCC Research Report on Hand Antiseptics
16 July 2009 - 11:00PM
Marketwired
BioTech Medics, Inc. (PINKSHEETS: BMCS) announced today that BCC
Research of Massachusetts advised BioTech Medics, Inc. that its
patented proprietary SHBAN(TM) Antiviral Hand Sanitizer Solution
was one of the antiseptic products cited in their major research
study.
Increasing consumer awareness of the dangers of H5N1 Avian Bird
Influenza and H1N1 (Swine) Influenza A as well as staph infections
together with various bacteria and fungus microbes has led to an
increased use of hand sanitizers.
The BCC Report highlights that the global market for antiseptics
and disinfectants reached $3.1 billion in 2008 and is projected to
reach $4.9 billion by 2013 at a compound annual growth rate of
9.6%.
BioTech is now poised to capture a portion of the worldwide
antiviral/antimicrobial solution market. BioTech has been
negotiating with various interested parties for acquiring a SHBAN
Distributorship. BioTech will be announcing soon the establishment
of its first offshore Distributorship.
SHBAN is a bio-degradable product superior to most anti-viral
and anti-bacterial disinfectants because 1) SHBAN is longer
lasting, SHBAN does not evaporate within 15 seconds after
application and cease working (like alcohol gels); 2) SHBAN is
non-toxic when used as directed on humans and animals; 3) SHBAN is
non-staining, non-bleaching; 4) SHBAN is non-flammable and 5) SHBAN
has no harmful or toxic odors. Most hand sanitizer products cannot
make all of these claims.
BioTech currently sells a 3 oz SHBAN(TM) Go Anywhere Hand
Atomizer Spray Bottle that complies with TSA carry-on travel
regulations. SHBAN sales are up significantly in 2009. BioTech is
releasing soon 1 oz and 16 oz bottles together with SHBAN Hand Wipe
Towelettes.
In 2007 BioTech conducted an independent study to determine the
efficacy of virucidal SHBAN against Avian H5N1 Influenza NIBRG-14
Virus. BioTech reported that the SHBAN Solution had clinically
proven its anti-viral properties and had topically killed the Avian
Influenza virus. Significantly, SHBAN was proven non-toxic with "no
cytotoxicity observed on the MDCK cell line after treatment." SHBAN
efficacy is being tested on H1N1 Swine Influenza at this time.
Safe Harbor: Forward-Looking Statements
This release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995
(the "Act"). The statements above have not been evaluated by the
FDA. SHBAN is not intended to diagnose, treat or cure any
disease.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Tom Wood Sr. V.P. Sales Phone 972-849-3782
BioTech Medics (PK) (USOTC:BMCS)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioTech Medics (PK) (USOTC:BMCS)
Historical Stock Chart
From Jul 2023 to Jul 2024